作者: Joseph B. Hiatt , David MacPherson
DOI: 10.1158/2159-8290.CD-19-0234
关键词: DNA 、 Non small cell 、 Blockade 、 Cancer research 、 DNA damage 、 Medicine 、 Immune checkpoint
摘要: Small cell lung cancer (SCLC) has demonstrated modest responses to immune-checkpoint blockade despite harboring a high mutational burden. In this issue, Sen and colleagues show remarkable synergy between inhibition of the DNA-damage response PD-1 axis, resulting in striking tumor regressions SCLC mouse models.See related article by et al., p. 646.